[1]李敏州,武忠,张瑞霞,等.中药太灵丹对STZ诱导糖尿病肾病大鼠肾脏保护作用的影响[J].西部中医药,2018,31(12):5-9.
　LI Minzhou,WU Zhong,ZHANG Ruixia,et al.Effects of TaiLing Pills on Renal Protection of the Rats with STZ-induced Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2018,31(12):5-9.
点击复制

中药太灵丹对STZ诱导糖尿病肾病大鼠肾脏保护作用的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年12期
页码:
5-9
栏目:
出版日期:
2018-12-15

文章信息/Info

Title:
Effects of TaiLing Pills on Renal Protection of the Rats with STZ-induced Diabetic Nephropathy
文章编号:
1004-6852(2018)12-0005-05
作者:
李敏州，武忠，张瑞霞，高巍，赵凯莹
内蒙古自治区人民医院中医科，内蒙古 呼和浩特 010017
Author(s):
LI Minzhou, WU Zhong, ZHANG Ruixia, GAO Wei, ZHAO Kaiying
TCM Department, Inner Mongolia People′s Hospital, Hohehot 010017, China
关键词:
糖尿病肾病; 太灵丹; 肾小管上皮细胞转分化; 肾脏纤维化; 动物实验
Keywords:
diabetic nephropathy; TaiLing pills; tubular epithelial mesenchymal trans-differentiation; renal fibrosis;  animal experiments
分类号:
R578.2
摘要:
目的：探讨中药太灵丹对链脲佐菌素(STZ)诱导糖尿病肾病大鼠肾脏保护作用的影响。方法：选择70只Wistar大鼠，根据体质量随机分为正常对照组10只，其余60只采用STZ诱导为糖尿病肾病大鼠模型，并分为模型组，太灵丹低剂量组［生药5 g/(kg·d)灌胃]、中剂量组［生药10 g/(kg·d)灌胃]、高剂量组［生药20 g/(kg·d)灌胃]及缬沙坦组［缬沙坦10 mg/(kg·d)灌胃］，每组12只。连续处理14周，检测各组大鼠体质量、血糖、糖化血红蛋白(HAblc)、24小时尿蛋白定量、血肌酐(Scr)、尿素氮(BUN)及甘油三酯(TG)的变化。用HE、PAS及Masson染色法观察肾脏病理改变。用免疫组织化学法检测肾组织转化生长因子β1(TGF-β1)、E-钙黏蛋白(E-cadherin)及α-平滑肌肌动蛋白(α-SMA)的表达。结果：1)模型组血糖、HAb1c、24小时尿蛋白定量指标均较正常对照组大鼠明显升高(P＜0.01或0.05)。病理学观察模型组大鼠肾小球肥大，基底膜增厚，细胞外基质增多及肾小管上皮细胞大量萎缩、空泡变性，间质内炎性细胞浸润。太灵丹各剂量组、缬沙坦组，上述改变较模型组明显减轻(P＜0.05)，但组间比较差异无统计学意义(P＞0.05)。2)免疫组化显示：与正常对照组比较，模型组肾小管上皮细胞中E-cadherin表达减弱(P＜0.05)，TGF-β1及α-SMA表达增强(P＜0.01)。太灵丹各剂量组及缬沙坦组，E-cadherin表达增强(P＜0.05)，TGF-β1及α-SMA表达减弱(P＜0.05)，但组间比较差异无统计学意义(P＞0.05)。结论:太灵丹可能通过增强E-cadherin、减弱TGF-β1及α-SMA的表达改善肾小管上皮细胞转分化，从而减缓糖尿病肾间质纤维化的进展。
Abstract:
Objective：To discuss the effects of TaiLing pills on renal protection of the rats with STZ-induced diabetic nephropathy. Methods：Seventy Wistar rats were allocated to ten rats in normal control group and other 60 rats, which were induced into the models suffering diabetic nephropathy by STZ, and separated into the model group, low ［intragastric administration of crude drug, 5g/(kg·d)］, moderate ［intragastric administration of crude drug, 10g/(kg·d)］ and high ［intragastric administration of crude drug, 20g/(kg·d)］ dosages groups of TaiLing pills and valsartan group ［intragastric administration of valsartan, 10mg/(kg·d)］, 12 rats each group. The changes of triglyceride(TG), blood usea nitrogen(BUN), serum creatinine(Scr), 24h urinary protein quantification, glycosylated hemoglobin(HAb1c), blood glucose and body mass were detected after the rats were handled consecutively for 14 weeks. Pathological changes of the kidney were observed by HE, PAS and Masson staining method, and the expressions of α-Smooth muscle actin(α-SMA), E-cadherin and TGF-β1 in renal tissue were measured by immunoh-istochemical method. Results: 1)Blood glucose, HAb1c and the indexes of 24h urinary protein quantification of the rats in the model group rose obviously compared with normal control group(P＜0.01 or 0.05). Pathological results showed that glomerular hypertrophy, basement membrane thickening, extracellular matrix increased and renal tubular epithelial cell shrank largely, vacuolar degeneration, interstitial inflammatory cells infiltrated in the model group. The changes above in different dosages groups of TaiLing pills and valsartan group relieved notably compared with the model group(P＜0.05), but the differences had no statistical meaning in the comparisons among the groups(P＞0.05). 2) Immunohistochemical results displayed that: compared with normal control group, the expressions of E-cadherin in renal tubular epithelial cells reduced in the model group(P＜0.05), the expressions of TGF-β1 and α-SMA enhanced (P＜0.01). The expressions of E-cadherin strengthened, the expressions of TGF-β1 and α-SMA reduced (P＜0.05) in different dosages groups of TaiLing pills and valsartan group, while the difference had no statistical meaning in the comparisons among the groups(P＞0.05). Conclusion：TaiLing pills could improve renal tubular epithelial cell trans-differentiation by enhancing the expressions of E-cadherin, reducing the expressions of TGF-β1 and α-SMA, therefore to delay the progression of interstitial fibrosis of DN patients.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):62.
[3]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(12):77.
[4]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(12):96.
[5]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):68.
[8]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):1.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):96.

备注/Memo

备注/Memo:
收稿日期：2018-03-26 *基金项目：内蒙古自治区自然科学基金项目(编号2014BS0810);内蒙古自治区人民医院博士科研启动资金(编号BS201516)。 作者简介：李敏州(1983—)，女，博士学位，副主任医师。研究方向：中医药防治糖尿病及其并发症。
更新日期/Last Update: 2018-12-15